# Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

> **NCT05096715** · PHASE1 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **RADIATION:** Stereotactic body radiation therapy (SBRT)

## Key facts

- **NCT ID:** NCT05096715
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-23
- **Primary completion:** 2027-01-31
- **Final completion:** 2032-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096715, "Atezolizumab+Bevacizumab+SBRT in Unresectable HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05096715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*